NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disease and PATrOL™-Enabled Therapy on September 16th
PITTSBURGH, Sept. 09, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Huntington's disease and NeuBase’s peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform on Monday, September 16, 2019 in New York City.
The meeting will feature presentations by KOL George Church, PhD, professor of genetics at Harvard Medical School, and Robert Friedlander, MD, chairman of the Department of Neurological Surgeons University of Pittsburgh Medical Center and the University of Pittsburgh Medical School, who will discuss Huntington's disease, the current treatment landscape and the genomic revolution culminating in the NeuBase technology platform. Dr. Church and Dr. Friedlander will be available to answer questions at the conclusion of the event.
Members of the Company's management team, including the inventor of the PATrOL technology and Chief Scientific Officer, Danith Ly, PhD, will provide an overview of NeuBase's PATrOL platform. PATrOL-enabled NT0100 is currently in preclinical development for the treatment of Huntington's disease.
Dr. Church is a pioneer of genome engineering, DNA sequencing and synthetic biology. He has cofounded 24 biotechnology companies, authored over 500 papers and 140 patent publications. Dr. Church is professor of genetics at Harvard Medical School and professor of health sciences and technology at Massachusetts Institute of Technology and Harvard Medical School. He is the director of the Center for Genomically Engineered Organs (CGEO), the Harvard DOE Technology Center, the Lipper Center for Computational Genetics and is a founding core member of the Wyss Institute for Biologically Inspired Engineering. Dr. Church is a member of the National Academy of Sciences (2011) and the National Academy of Engineering (2012) and has received the Franklin Institute’s Bower Award for Achievement in Science (2011). He holds a Ph.D. in biochemistry and molecular biology from Harvard University.
Dr. Friedlander is a renowned neurologist. He is the fourth chairman of the Department of Neurological Surgeons at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center. Prior to joining the department, Dr. Friedlander was professor of neurosurgery at Harvard Medical School and vice-chairman of neurosurgery and associate director of cerebrovascular surgery at Brigham and Women’s Hospital in Boston. Presently, Dr. Friedlander is the Walter E. Dandy Professor of Neurosurgery, Neurology and Neurobiology, and Co-Director of the UPMC Neurological Institute. His work has been published in many top tier journals including Nature, Science, Nature Medicine, Nature Neuroscience and PNAS, and he has been recognized through many academic awards. In 2006, he was elected as a member of the prestigious American Society for Clinical Investigation. Dr. Friedlander is one of only three neurosurgeons elected as a member of the American Association of Physicians, and in 2018, he was elected to the National Academy of Medicine.
Dr. Ly is the primary inventor of NeuBase's PATrOL™ platform. He has over 30 years of research and development experience in nucleic acids chemistry and functional genomics, and an extensive publication report. His work has appeared in numerous high-profile journals, including Science, Nature Communications, Nature Communications Chemistry, Proceeding of the National Academy of Science and the Journal of the American Chemical Society. He is currently a professor of chemistry and a founding director of the Biomolecular Design and Discovery Institute (BDI) at Carnegie Mellon University. Dr. Ly holds a Ph.D. in organic chemistry from the Georgia Institute of Technology and completed postdoctoral fellowships at the University of California Berkeley and The Scripps Research Institute, in genomics and age-related genetic disease, respectively.
This event is intended for institutional investors, sell-side analysts and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast.
About NeuBase Therapeutics
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of genomic loci or secondary and tertiary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the Company’s prospects, opportunities, goals and plans. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those described in the risk factors contained in the Company’s registration statement on Form S-4, as amended, that contains a joint proxy statement/prospectus, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: risks regarding the Company’s plans to develop and commercialize its product candidates; the timing of initiation of the Company’s planned clinical trials; the timing of the availability of data from the Company’s clinical trials; the timing of any planned investigational new drug application or new drug application; the Company’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company’s product candidates; the Company’s commercialization, marketing and manufacturing capabilities and strategy; the Company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risks discussed under the heading "Risk Factors" in Ohr’s registration statement on Form S-4, as amended, that contains a joint proxy statement/prospectus. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
NeuBase Investor Contact:
LifeSci Advisors, LLC
OP: (617) 535-7746
NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
OP: (646) 751-4366
Released September 9, 2019